• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
By ANDERS KEITZ Aug 24, 2016 | 05:27 PM EDT
Stocks quotes in this article: PFE, MDVN, NKE, DKS, TJX, FL, AZN

Pfizer (PFE)  has been busy lately, but its latest acquisition could add to integration risk.

The company announced early Wednesday that it will acquire the small-molecule anti-infective business from AstraZeneca (AZN) . This follows Monday's announcement that Pfizer plans to acquire Medivation (MDVN) to propel the company into a leading position in oncology.

For the AstraZeneca acquisition, Pfizer will pay Astra $550 million up front and an unconditional $175 million in January 2019. Then, depending on the progress and success of the drugs, it will pay another $850 million plus royalties.

Dividend Stock Advisor's portfolio manager David Peltier said in a note to subscribers Wednesday that the company may need to slow down. "Any additional purchase that management makes will add to its execution risk in the coming quarters," Peltier wrote.

Meanwhile, as we head into back-to-school season, one sports retailer is catching the eye of other portfolio managers. Trifecta Stocks' Chris Versace and Bob Lang say Nike (NKE)  is benefiting from "the increasingly bullish outlook for athletic footwear and apparel." Foot Locker (FL) and Dick's Sporting Goods (DKS) highlighted the bullishness in each of their respective earnings reports last week. 

Apparel retailer TJ Maxx (TJX) presents another potential opportunity for gains. Action Alerts PLUS portfolio managers Jim Cramer and Jack Mohr believe the market is discounting management's ability to beat their historically conservative guidance.

"TJX has a history of under-promising and over-delivering, which is also favorable compared to the opposite, and we are willing to wait out the choppiness in the short term for the longer-term upside opportunity, which is driven by TJX's unique ability to drive traffic through its stores despite the current 'Amazon-ian' marketplace that is retail," Cramer and Mohr wrote in a note to subscribers Monday.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Consumer Discretionary | Earnings | Mergers and Acquisitions

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • 08:09 AM EST GARY BERMAN

    Monday Morning Fibocall for 3/1/2021

    Always a good idea to know where our bounce zones ...
  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login